Abstract
The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting. The effects of doxazosin on office blood pressure, changes in lipid profiles, and theoretic coronary disease risk were studied. In an open, noncomparative, multicenter trial, 851 patients were studied for a maximum of 16 weeks. Doxazosin significantly reduced mean sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) by 15.2/12.5 mm Hg and standing SBP and DBP by 16.1/12.7 mm Hg in the total study population (n = 807; p = 0.0001), with no significant effect on heart rate. Mean total cholesterol levels were significantly reduced by 2.7%, low-density lipoprotein cholesterol levels by 2.4%, and mean triglyceride levels by 3.4% (all p values < 0.05). High-density lipoprotein (HDL) cholesterol levels were essentially unchanged. The mean ratio of total to HDL cholesterol was significantly reduced (p < 0.05). Mean predicted 5-year coronary disease risk was significantly reduced with doxazosin therapy by 14.7% in previously untreated patients (p < 0.0001) and by 1.7% in patients who were previously receiving antihy...Continue Reading
References
Aug 3, 1991·BMJ : British Medical Journal·Z ChenW Li
Jan 1, 1991·Circulation·K M AndersonW B Kannel
Dec 1, 1990·Circulation·I Holme
Apr 29, 1989·BMJ : British Medical Journal·T PollareC Berne
Aug 16, 1989·The American Journal of Medicine·J L PoolE B Nelson
Sep 28, 1989·The New England Journal of Medicine·T PollareC Berne
Feb 14, 1986·The American Journal of Medicine·M H Weinberger
Jul 1, 1988·Diabetologia·T PollareC Berne
Nov 19, 1987·The New England Journal of Medicine·W C WillettC H Hennekens
Nov 28, 1986·JAMA : the Journal of the American Medical Association·W P CastelliW B Kannel
Nov 1, 1985·American Heart Journal·W B Kannel
Jan 20, 1984·JAMA : the Journal of the American Medical Association
Feb 1, 1982·Diabetologia·R J JarrettH Keen
Citations
Feb 20, 2007·Postgraduate Medical Journal·Stephen S Connolly, John M Fitzpatrick
Feb 13, 1999·Journal of Clinical Pharmacology·W H Frishman, F Kotob
Jun 5, 2002·Congestive Heart Failure·Domenic A Sica
Jan 11, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN JCS Joint Working Group
Jul 29, 2010·Clinical and Experimental Hypertension : CHE·Kenta GonokamiYutaka Imai
May 2, 2001·Current Medical Research and Opinion·D P MikhailidisR J Morgan
Mar 9, 2006·The Journal of Clinical Hypertension·Samuel J Mann
Jan 11, 2005·Clinical Therapeutics·Franklin C Lowe
Feb 6, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshio IkedaNami Matsuda
Jun 2, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yuko OhtaMichio Ueno
Jun 24, 2015·Current Opinion in Lipidology·Tarza J SiahmansurHandrean Soran
Apr 29, 2006·American Heart Journal·J Conor O'Shea, Robert M Califf
Dec 29, 1998·Journal of Clinical Pharmacy and Therapeutics·Y H YuenJ C Chan
Apr 12, 2005·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·John A PapadakisEmmanuel S Ganotakis
May 26, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·S M Marshall
Aug 29, 2017·Medicina·Ingrida LisauskienėJolanta Gulbinovič
Jun 9, 2007·Circulation Research·Noriyuki IwamotoShinji Yokoyama
Jul 21, 2007·Circulation Research·Alan T Remaley
Jun 15, 2010·Journal of Hypertension·Neil ChapmanBryan Williams
May 29, 2000·American Journal of Hypertension·H R BlackJ L Garofalo
Aug 19, 2000·American Journal of Hypertension·S NalbantgilR Onder